Compare REGN & CL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | CL |
|---|---|---|
| Founded | 1988 | 1806 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2B | 68.8B |
| IPO Year | 1995 | 2008 |
| Metric | REGN | CL |
|---|---|---|
| Price | $638.39 | $88.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 17 |
| Target Price | ★ $830.16 | $94.19 |
| AVG Volume (30 Days) | 1.0M | ★ 4.5M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | 0.55% | ★ 2.51% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 6.75 | 0.80 |
| Revenue | $5,872,227,000.00 | ★ $15,454,000,000.00 |
| Revenue This Year | $12.45 | $7.49 |
| Revenue Next Year | $10.13 | $3.28 |
| P/E Ratio | ★ $93.13 | $106.34 |
| Revenue Growth | ★ 20.82 | 1.70 |
| 52 Week Low | $494.42 | $74.55 |
| 52 Week High | $821.11 | $99.33 |
| Indicator | REGN | CL |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 52.20 |
| Support Level | $610.60 | $76.17 |
| Resistance Level | $783.87 | $89.34 |
| Average True Range (ATR) | 15.40 | 2.11 |
| MACD | 1.54 | -0.49 |
| Stochastic Oscillator | 80.31 | 55.44 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Since its founding in 1806, Colgate-Palmolive has grown into a leading player in the household and personal care industry. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and home care products sold in over 200 countries. International sales account for about 70% of its total business, including nearly half from emerging regions. It also owns specialty pet food maker Hill's (almost one-fourth of sales), which sells the majority of its products through veterinarians and specialty pet retailers.